The US Food and Drug Administration (FDA) has approved Transcept Pharmaceuticals’ Intermezzo (zolpidem tartrate) C-IV, used to treat insomnia.
Intermezzo is available in doses of 1.75mg and 3.5mg as a sublingual tablet that contains a bicarbonate-carbonate buffer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Women are recommended to take the 1.75mg dosage, while the 3.5mg is intended for men, as because women clear zolpidem from the body at a slower rate, the company said.
The approval is backed by two placebo-controlled studies which evaluated the safety and efficacy of Intermezzo for the treatment of patients with insomnia.
